Streck’s A1c‐Cellular®, the first and only HbA1c control on the market with intact red blood cells, is now assayed for the Roche Cobas® 6000 and Ortho-Clinical Diagnostics VITROS® 5600.
Streck’s A1c-Cellular tests the entire HbA1c procedure, including the lysing of the red blood cell—a step omitted with other controls. This important step ensures the entire system, instrument and reagents, is working properly and provides accurate patient results. A1c-Cellular does not need to be reconstituted, which eliminates the potential for human error due to incorrect pipetting during reconstitution, and is convenient to use.
A1c-Cellular is appropriate for immunoassay and ionic exchange HPLC methodologies and is also assayed for the Ortho-Clinical Diagnostics VITROS 5, 1 FS; Arkray Menarini ADAMS™ A1c HA-8160; Beckman Coulter® Synchron CX®/LX® and UniCel® DxC 600/800 Synchron®; Bio-Rad® D10/Variant II™/Variant II Turbo; Siemens Healthcare Diagnostics Inc Dimension Series; Roche Cobas Integra®; and the Tosoh A1c 2.2 Plus/G7/G8.
Available in 2.0ml plastic screw‐top cap-pierceable vials, A1c-Cellular offers a closed-vial stability of six months and an open-vial stability of 30 days.
Source: Streck
